Company: ZDAN
Filing Date: 2025-02-18
Form Type: DRS/A
Source: 0001683168-25-001085
Chunk: 267

Company: Zerolimit Technology Holding Co. Ltd.
Filing Date: 2025-02-18
Form: DRS/A
Chunk 267
---
s to our Company before expenses |     | $                 |     | $ |                   |     | $                 |     | $                 |

| 166 |

We estimate expenses payable
to us in connection with this offering, other than the underwriting discounts referred to above, will be approximately $[·].
We have agreed to pay to the Underwriter a non-accountable fee of 1% of the aggregate offering amount upon closing of this offering.
We have also agreed to reimburse the Underwriter for all of its reasonable out-of-pocket expenses, including but not limited to reasonable
fees and expenses of its legal counsel, roadshow expenses, background check fee, offering materials, and necessary travel expenses in
an aggregate amount not to exceed $200,000 in connection with the offering. We have advanced $50,000 to the Underwriter (the “Advance”).
The Advance will be returned to us to the extent the Underwriter’s out-of-pocket accountable expenses are not actually incurred
in accordance with FINRA Rule 5110(g)(4)(A).

Listing

We plan to list our Ordinary
Shares on the Nasdaq Capital Market under the symbol “ZDAN.” At this time, we have not yet applied to Nasdaq to list our
Ordinary Shares. The closing of this offering is conditioned upon Nasdaq’s final approval of our listing application, and there
is no guarantee or assurance that our Ordinary Shares will be approved for listing on Nasdaq.

Underwriter’s Warrants

In addition, we have agreed
to issue warrants to the Underwriter to purchase a number of Ordinary Shares equal to five percent (5%) of the total number of Ordinary
Shares sold in this offering, including shares issued pursuant to the exercise of the over-allotment option (the “Underwriter’s
Warrants”). Such warrants shall have an exercise price equal to 125% of the offering price of the Ordinary Shares sold in this
offering. The Underwriter’s Warrants will be exercisable, commencing six months from the effective date of offering, and will expire
on the fifth anniversary of the commencement of sales under this offering. The Underwriter’s Warrants and the underlying Ordinary
Shares will be deemed compensation by FINRA, and therefore will be subject to FINRA Rule 5110(e)(1). In accordance with FINRA Rule 5110(e)(1),
and except as otherwise permitted by FINRA rules, neither the Underwriter’s Warrants nor any of our Ordinary Shares issued upon
exercise of